{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T18:14:56Z","timestamp":1725473696615},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.ijantimicag.2006.05.014","type":"journal-article","created":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T15:01:58Z","timestamp":1153321318000},"page":"108-112","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice"],"prefix":"10.1016","volume":"28","author":[{"given":"Sang Don","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Kon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duck Ki","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luck Hee","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Soo","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bong Suk","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Eui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Bang","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Gon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Yul","family":"Rhew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Hyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2006.05.014_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0924-8579(94)90019-1","article-title":"Quinolones in the treatment of complicated urinary tract infection","volume":"4","author":"Graninger","year":"1994","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib2","series-title":"Principles and practice of infectious diseases","author":"Mandell","year":"1990"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2006.05.014_bib3","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1007\/BF01710009","article-title":"Urinary tract infections in the 90s: pathogenesis and management","volume":"20","author":"Andriole","year":"1992","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0002-9343(92)90312-Y","article-title":"Urinary tract infections","volume":"92","author":"Neu","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.7326\/0003-4819-110-2-138","article-title":"Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis and treatment","volume":"110","author":"Lipsky","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0090-4295(98)00034-X","article-title":"Prevalence of a physician diagnosis of prostatitis: the Olmstead County study of urinary symptoms and health status among men","volume":"51","author":"Roberts","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib7","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.36.10.2108","article-title":"In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone","volume":"36","author":"Hosaka","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.41.6.1331","article-title":"In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlyamidia spp.","volume":"41","author":"Miyashita","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-5347(05)68562-X","article-title":"The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure","volume":"162","author":"Litwin","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib10","first-page":"47","article-title":"Clinical study of the efficacy and safety of single-dose rufloxacin and 3-day norfloxacin treatments for acute urinary tract infections","volume":"18","author":"Kim","year":"2000","journal-title":"J Korean Soc Chemother"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and a sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference of non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/clinids\/18.1.1","article-title":"Urinary tract infections in females","volume":"18","author":"Kunin","year":"1994","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2006.05.014_bib13","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1093\/clind\/15.Supplement_1.S216","article-title":"Evaluationof new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration","volume":"15","author":"Rubin","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib14","doi-asserted-by":"crossref","first-page":"13991","DOI":"10.1073\/pnas.94.25.13991","article-title":"DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance","volume":"94","author":"Zhao","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0732-8893(02)00444-3","article-title":"Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES)","volume":"44","author":"Mandell","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1464-410X.2000.00836.x","article-title":"Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study","volume":"86","author":"Mehik","year":"2000","journal-title":"BJU Int"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2006.05.014_bib17","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.ijantimicag.2004.02.009","article-title":"NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelines for bacterial prostatitis","volume":"24","author":"Schaeffer","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib18","series-title":"Quinolone antimicrobial agents","first-page":"285","article-title":"Role of quinolones in treatment of chronic bacterial prostatitis","author":"Naber","year":"1993"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/AAC.45.1.293-297.2001","article-title":"Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400mg to volunteers","volume":"45","author":"Naber","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib20","first-page":"12","article-title":"Mechanisms of action and resistance to ciprofloxacin","volume":"82","author":"Hooper","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib22","first-page":"1225","article-title":"Urinary tract infections in adults","volume":"59","author":"Orenstein","year":"1999","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/j.1532-5415.2001.49268.x","article-title":"Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim: sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection","volume":"49","author":"Gomolin","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib24","series-title":"Adverse effects. Quinolone antimicrobial agents","first-page":"489","year":"1993"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003495-199958002-00009","article-title":"Quinolones in the aged","volume":"58","author":"Nicolle","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002512-200320040-00005","article-title":"Fluoroquinolones in the elderly: safety considerations","volume":"20","author":"Stahlmann","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijantimicag.2003.12.017","article-title":"Gatifloxacin 400mg as a single shot or 200mg once daily for 3 days is as effective as ciprofloxacin 250mg twice daily for the treatment of patients with uncomplicated urinary tract infections","volume":"23","author":"Naber","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/S1413-86702003000100007","article-title":"An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers","volume":"7","author":"Nicodemo","year":"2003","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.05.014_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002512-200320040-00005","article-title":"Fluoroquinolones in the elderly: safety considerations","volume":"20","author":"Stahlmann","year":"2003","journal-title":"Drugs Aging"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2006.05.014_bib30","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ijantimicag.2003.09.002","article-title":"Gatifloxacin 200mg or 400mg once daily is as effective as ciprofloxacin 500mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections","volume":"23","author":"Naber","year":"2004","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790600166X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790600166X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T04:20:09Z","timestamp":1555734009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485790600166X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":30,"alternative-id":["S092485790600166X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.05.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}